强生-话题@MedSci

#强生#

169篇内容 | 4613人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271765, encodeId=9cea12e176503, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA缩小了强生COVID-19疫苗Ad26.COV2.S的使用范围, objectType=article, longId=726367, objectId=e3ffe2636755, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3ffe2636755, replyNumber=0, likeNumber=123, createdTime=2022-05-09, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3ffe2636755, moduleTitle=FDA缩小了强生COVID-19疫苗Ad26.COV2.S的使用范围, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3ffe2636755)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271764, encodeId=69bf12e1764ed, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=突发！强生腺病毒载体新冠疫苗因血栓风险，被FDA限制授权使用, objectType=article, longId=726293, objectId=2a50e26293e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a50e26293e8, replyNumber=0, likeNumber=107, createdTime=2022-05-08, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a50e26293e8, moduleTitle=突发！强生腺病毒载体新冠疫苗因血栓风险，被FDA限制授权使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a50e26293e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271763, encodeId=65c112e1763ed, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生历史很大改组，计划剥离消费者保健业务以专注于药品和器械, objectType=article, longId=220273, objectId=13be2202e3f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13be2202e3f6, replyNumber=0, likeNumber=128, createdTime=2021-11-15, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13be2202e3f6, moduleTitle=强生历史很大改组，计划剥离消费者保健业务以专注于药品和器械, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13be2202e3f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271761, encodeId=102912e1761eb, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA咨询机构认可强生COVID-19疫苗加强针, objectType=article, longId=218762, objectId=4252218e6226, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4252218e6226, replyNumber=0, likeNumber=139, createdTime=2021-10-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4252218e6226, moduleTitle=FDA咨询机构认可强生COVID-19疫苗加强针, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4252218e6226)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271760, encodeId=60f712e176043, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生表示，新冠加强注射针有效率高达94%！, objectType=article, longId=217475, objectId=cf3021e475cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf3021e475cf, replyNumber=0, likeNumber=117, createdTime=2021-09-24, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf3021e475cf, moduleTitle=强生表示，新冠加强注射针有效率高达94%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf3021e475cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271759, encodeId=0e1912e17590c, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生HIV疫苗重大试验失败，HIV疫苗研发依然面临挑战, objectType=article, longId=217093, objectId=ab8f21e09342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab8f21e09342, replyNumber=0, likeNumber=124, createdTime=2021-09-16, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab8f21e09342, moduleTitle=强生HIV疫苗重大试验失败，HIV疫苗研发依然面临挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab8f21e09342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271762, encodeId=8de112e17627c, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=罗氏诊断与九强生物共同推出全新二代生化试剂盒，打造外诊断领域全新格局, objectType=article, longId=216070, objectId=12ae2160e00f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12ae2160e00f, replyNumber=0, likeNumber=78, createdTime=2021-08-22, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12ae2160e00f, moduleTitle=罗氏诊断与九强生物共同推出全新二代生化试剂盒，打造外诊断领域全新格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12ae2160e00f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271758, encodeId=37eb12e1758e5, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=JAMA: 阿斯利康、杨森/强生COVID-19疫苗引起脑静脉窦血栓形成和血小板减少又添新佐证, objectType=article, longId=215031, objectId=ced7215031a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced7215031a6, replyNumber=0, likeNumber=115, createdTime=2021-07-31, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced7215031a6, moduleTitle=JAMA: 阿斯利康、杨森/强生COVID-19疫苗引起脑静脉窦血栓形成和血小板减少又添新佐证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced7215031a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271757, encodeId=40a012e17576f, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=关注房颤防治，守护心脑健康——强生医疗携手北京白求恩公益基金会启动2021中国房颤日大型疾病科普公益传播项目, objectType=article, longId=212352, objectId=94302123523e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94302123523e, replyNumber=0, likeNumber=85, createdTime=2021-06-08, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94302123523e, moduleTitle=关注房颤防治，守护心脑健康——强生医疗携手北京白求恩公益基金会启动2021中国房颤日大型疾病科普公益传播项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94302123523e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271756, encodeId=290212e17566d, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=欧盟EMA发现强生新冠疫苗可能与血栓有关，但表示获益大于风险, objectType=article, longId=210253, objectId=93e8210253cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e8210253cb, replyNumber=0, likeNumber=123, createdTime=2021-04-22, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e8210253cb, moduleTitle=欧盟EMA发现强生新冠疫苗可能与血栓有关，但表示获益大于风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e8210253cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271755, encodeId=8d8112e175524, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生疫苗或导致血栓，腺病毒载体疫苗还安全吗？, objectType=article, longId=209838, objectId=60f620983808, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60f620983808, replyNumber=0, likeNumber=154, createdTime=2021-04-13, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60f620983808, moduleTitle=强生疫苗或导致血栓，腺病毒载体疫苗还安全吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60f620983808)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271754, encodeId=903912e17548f, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=1500万剂强生新冠疫苗因制造错误而丢弃, objectType=article, longId=209313, objectId=a78e209313f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a78e209313f2, replyNumber=0, likeNumber=84, createdTime=2021-04-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a78e209313f2, moduleTitle=1500万剂强生新冠疫苗因制造错误而丢弃, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a78e209313f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271753, encodeId=cbe212e175304, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=武田和IDT为强生COVID-19疫苗生产提供支持, objectType=article, longId=208551, objectId=2472208551a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2472208551a5, replyNumber=0, likeNumber=149, createdTime=2021-03-19, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2472208551a5, moduleTitle=武田和IDT为强生COVID-19疫苗生产提供支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2472208551a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271752, encodeId=9d9d12e175292, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=为何世卫批准辉瑞、阿斯利康、强生等疫苗，中俄新冠疫苗迟迟未被批准？, objectType=article, longId=208395, objectId=e5782083951b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5782083951b, replyNumber=0, likeNumber=125, createdTime=2021-03-16, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5782083951b, moduleTitle=为何世卫批准辉瑞、阿斯利康、强生等疫苗，中俄新冠疫苗迟迟未被批准？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5782083951b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271751, encodeId=22a612e175133, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=美FDA发布强生研发的疫苗分析报告：能预防中度至重度新冠感染, objectType=article, longId=207994, objectId=ce1820e994e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce1820e994e9, replyNumber=0, likeNumber=91, createdTime=2021-03-08, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce1820e994e9, moduleTitle=美FDA发布强生研发的疫苗分析报告：能预防中度至重度新冠感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce1820e994e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271750, encodeId=274a12e175095, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生COVID-19疫苗Ad26.COV2.S获得FDA专家组认可，有望成为美国批准的第三种疫苗, objectType=article, longId=207709, objectId=a5d720e709d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5d720e709d3, replyNumber=0, likeNumber=110, createdTime=2021-03-01, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5d720e709d3, moduleTitle=强生COVID-19疫苗Ad26.COV2.S获得FDA专家组认可，有望成为美国批准的第三种疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5d720e709d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271749, encodeId=62e012e1749bc, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生新冠疫苗III期研究成功，单次接种预防中重度COVID-19有效率66%！即将向FDA提交紧急使用授权申请, objectType=article, longId=206583, objectId=ab6920658334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6920658334, replyNumber=0, likeNumber=113, createdTime=2021-02-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6920658334, moduleTitle=强生新冠疫苗III期研究成功，单次接种预防中重度COVID-19有效率66%！即将向FDA提交紧急使用授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6920658334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271748, encodeId=ba0612e17481a, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, objectType=article, longId=206565, objectId=0ffe20656522, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ffe20656522, replyNumber=0, likeNumber=188, createdTime=2021-02-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ffe20656522, moduleTitle=强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ffe20656522)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271747, encodeId=b2d512e1747d8, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=2021年1月30日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿258万，强生单剂疫苗有效率为66%, objectType=article, longId=206436, objectId=d106206436b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d106206436b0, replyNumber=0, likeNumber=99, createdTime=2021-01-31, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d106206436b0, moduleTitle=2021年1月30日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿258万，强生单剂疫苗有效率为66%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d106206436b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271746, encodeId=86b012e174682, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生、直观外科正面PK，肺部介入机器人将成为新风口？, objectType=article, longId=206248, objectId=a191206248ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a191206248ff, replyNumber=0, likeNumber=121, createdTime=2021-01-27, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a191206248ff, moduleTitle=强生、直观外科正面PK，肺部介入机器人将成为新风口？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a191206248ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

强生

2020-05-29

柳叶一刀 (审核中...)

前往app查看评论内容

#强生#

FDA缩小了强生COVID-19疫苗Ad26.COV2.S的使用范围

2022-05-09

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

突发！强生腺病毒载体新冠疫苗因血栓风险，被FDA限制授权使用

2022-05-08

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生历史很大改组，计划剥离消费者保健业务以专注于药品和器械

2021-11-15

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA咨询机构认可强生COVID-19疫苗加强针

2021-10-19

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生表示，新冠加强注射针有效率高达94%！

2021-09-24

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生HIV疫苗重大试验失败，HIV疫苗研发依然面临挑战

2021-09-16

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

罗氏诊断与九强生物共同推出全新二代生化试剂盒，打造外诊断领域全新格局

2021-08-22

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

JAMA: 阿斯利康、杨森/强生COVID-19疫苗引起脑静脉窦血栓形成和血小板减少又添新佐证

2021-07-31

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

关注房颤防治，守护心脑健康——强生医疗携手北京白求恩公益基金会启动2021中国房颤日大型疾病科普公益传播项目

2021-06-08

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

欧盟EMA发现强生新冠疫苗可能与血栓有关，但表示获益大于风险

2021-04-22

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生疫苗或导致血栓，腺病毒载体疫苗还安全吗？

2021-04-13

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

1500万剂强生新冠疫苗因制造错误而丢弃

2021-04-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

武田和IDT为强生COVID-19疫苗生产提供支持

2021-03-19

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

为何世卫批准辉瑞、阿斯利康、强生等疫苗，中俄新冠疫苗迟迟未被批准？

2021-03-16

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

美FDA发布强生研发的疫苗分析报告：能预防中度至重度新冠感染

2021-03-08

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生COVID-19疫苗Ad26.COV2.S获得FDA专家组认可，有望成为美国批准的第三种疫苗

2021-03-01

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生新冠疫苗III期研究成功，单次接种预防中重度COVID-19有效率66%！即将向FDA提交紧急使用授权申请

2021-02-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生单剂新冠疫苗综合有效率达66%，康希诺继续推进Ad5-nCoV的III期临床试验

2021-02-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

2021年1月30日全球新冠肺炎（COVID-19）疫情简报，确诊超1亿258万，强生单剂疫苗有效率为66%

2021-01-31

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生、直观外科正面PK，肺部介入机器人将成为新风口？

2021-01-27

科室
- - 订阅+
  - 更多科室
工具
服务